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Abstract: Angiotensin II type 1 receptor antibodies (AT1RAb) have
emerged as non-HLA Ab present in patients with acute AMR and risk
of graft loss. Furthermore, AT1RAb have been shown to increase
angiotensin II sensitivity which may play a role in the development of
CVD and hypertension. Data on AT1RAb in stable transplant
recipients are lacking. The aim of this study was to analyze the levels of
AT1RAb in a cohort of stable patients after kidney transplantation (tx)
in childhood. A cross-sectional study of 30 children (median age 14,
range 3–19 yr, median time since tx five yr) and 28 adults who were
transplanted in childhood (median age 26, range 20–40 yr, median time
since tx 18 yr) transplanted between 1993–2006 and 1983–2002,
respectively, was performed. Healthy controls were 51 healthy children
(5–8 yr) and 199 healthy donors (median age 56.5 yr, range 42–83 yr).
Plasma AT1RAb were analyzed by immunoassay. Median total
AT1RAb IgG concentration was significantly higher in the pediatric-tx
group as compared to the adult-tx group (40.0 and 10.95 U/mL,
p < 0.0001). For both groups, the tx group showed higher levels: the
pediatric-tx group vs. control group (40.0 vs. 13.3 U/mL, p = 0.0006)
and the adult-tx group vs. adult control group (10.95 vs. 6.5 U/mL,
p < 0.0001). Age was the strongest indicator of high levels of AT1RAb
IgG (p = 0.0003). AT1RAb total IgG levels are significantly higher in a
stable pediatric-tx cohort as compared to adult-tx patients and healthy
controls of comparable age groups. The relevance of our findings in
relation to age, time since tx, previous or future rejection, and CVD
risk merits future studies.
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HLA antibodies (HLA Ab) have well-recognized
associations with graft failure in kidney trans-
plantation (1). However, not all cases of graft
loss can be explained by the presence of HLA Ab
even when there are histological findings consis-
tent with acute AMR. Subsequently, other non-
HLA antibodies have emerged as plausible cau-
sative agents, including AT1RAb. These Ab have
been found in patients with AMR and vascular
rejection (2). The presence of AT1RAb before
transplantation is proposed as a risk factor for
graft loss and has a strong association with graft
failure (3, 4). Still, the role of these autoantibod-
ies after tx a factor involved in rejection and graft
loss is not clear and under investigation (1).
Hypertension, a common complication after
renal transplantation (tx), occurs in 30–50% of all
kidney transplant recipients depending on the
method of blood pressure measurement, defini-
tion, and normative data used (5). Hypertension is
a risk factor for graft loss and CVD after kidney
Abbreviations: AMR, antibody-mediated rejection; AngII,
angiotensin II; AT1RAb, angiotensin II type 1 receptor anti-
bodies; BMI, body mass index; CAKUT, congenital
anomalies of the kidney and urinary tract; CHO, Chinese
hamster ovary; CVD, cardiovascular disease; DD, deceased
donor; ELISA, enzyme-linked immunosorbent assay;
ESRD, end-stage renal disease; FSGS, focal segmental
glomerulosclerosis; GFR, glomerular filtration rate; HENT,
health after kidney transplantation; IQR, interquartile
range; LD, living donors; MAP, mean arterial pressures;
NRR, Norwegian Renal Registry; RAS, renin–angiotensin
system; TRPCP6, transient receptor potential cation chan-
nel 6.
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tx (6). The etiology of hypertension after renal tx
is multifactorial and includes the type and degree
of native kidney disease, medication such as cal-
cineurin inhibitors and steroids, obesity, vascular
malformations, and reduced GFR (5). An acti-
vated RAS in the post-tx period is likely to con-
tribute to an increase in blood pressure; however,
detailed studies are lacking. Angiotensin II (AngII)
is a potent vasoconstrictor and also regulates the
water–salt balance through the AT1 receptor. In
addition, AngII acts as a pro-inflammatory cyto-
kine via the AT1 receptor, increases oxidative
stress, and contributes to vascular remodeling and
the pathogenesis of atherosclerosis (7). Similar
effects have been observed for AT1RAb, which
also activates the AT1 receptor.
Data on AT1RAb in pediatric kidney trans-
plant recipients are lacking, and, so far, only two
publications in children have been published.
One case report describes a girl with accelerated
acute C4d-positive kidney transplant rejection,
malignant hypertension, encephalopathy, and
the presence of both AT1RAb and HLA class II
Ab (8). A recent publication describes de novo
development of AT1RAb after kidney transplan-
tation in childhood (9).
The aim of this study was to explore the pres-
ence of AT1RAb in a cohort of tx patients with
stable kidney function and transplanted in child-




Ped-tx cohorts were children and adolescents between 3 and
19 yr who underwent transplantation at an age below 16 yr
between 1993 and 2006.
Adult-tx cohort: Adults (20–40 yr) having a renal trans-
plant during childhood (<16 yr of age undergoing first renal
tx between 1983 and 2002), aged >19 yr, were identified
from the NRR.
The transplanted patients were invited to participate in a
cross-sectional study, the HENT study, performed in 2008–
2010.
Inclusion criteria for the HENT study were a functioning
graft for at least one yr and no ongoing signs of rejection.
Written informed consent was obtained from patients and/or
their parents (if younger than 16 yr) prior to study start. The
HENT study protocol of the transplanted patients was
approved by the Regional Committee for Medical and Health
Research Ethics in South-Eastern Norway, and the study was
carried out according to the Declaration of Helsinki. Details
from the HENT study have previously been published (10–12).
Control groups
Healthy children control group: Blood samples from a
healthy group of fasting children aged 5–8 yr were used as
background control group for the transplanted child study
group. These healthy Norwegian children were included as
part of a longitudinal pregnancy follow-up study of mother
and children after pregnancy complications. Details from
this study have previously been published (13).
Adult healthy control group: A total of 199 healthy con-
trols were recruited at the University Hospitals of Goettingen,
Berlin, and Erlangen after informed consent was obtained.
Clinical information from the transplant groups
Causes of ESRD (pediatric-tx group and adult-tx group)
Causes of ESRD were CAKUT (n = 18), glomerulonephri-
tis (n = 9), nephronophthisis (n = 9), hemolytic uremic syn-
drome (n = 2), FSGS/congenital nephrotic syndrome
(n = 6), metabolic causes (n = 4), and other or unknown
(n = 10). For more detailed information, see Table 1.
Blood pressure
Hypertension in participants <19 yr of age was defined as a
blood pressure above the 95th centile for age, height, gen-
der, and/or using antihypertensive medication. Hyperten-
sion in adults was defined as a blood pressure >140/
90 mmHg and/or using antihypertensive medication.
Rejection
Data up to and including 2014 were retrieved retrospec-
tively and prospectively in regard to the HENT study
through medical charts and from the NRR concerning kid-
ney transplant rejection.
Acute rejection episodes were defined by an elevation in
serum creatinine of at least 20%, accompanied by antirejec-
tion therapy and/or accompanied by positive histological
findings. Rejections were not categorized further into acute
cellular, vascular, or AMR.
Angiotensin II type 1 receptor antibodies (AT1RAb)
measurement by ELISA
Concentrations of AT1RAb were measured by a sandwich
ELISA using a kit (CellTrend GmbH, Luckenwalde,
Germany) from EDTA plasma according to the manufac-
turer’s protocol. Extracts from transfected CHO cells
overexpressing the human AT1R were coated on microtiter
96-well polystyrene plates. Conformational epitopes of the
receptor were maintained by addition of 1 mM calcium chlo-
ride to every buffer. Samples were analyzed in duplicate in a
1:100 serum dilution after incubation at 48 °C for two h.
After washing steps, plates were incubated for 60 min with
a 1:20 000 dilution of horseradish peroxidase-labeled goat
anti-human IgG (Jackson, Bar Harbor, ME, USA) used for
detection. To obtain a standard curve, plates were incu-
bated with test sera from an anti-AT1RAb-positive index
patient. When compared to the neonatal cardiomyocyte
bioassay used in the first study (4), the solid-phase assay
had 96% specificity and 88% sensitivity. The interassay
variability was 8%; the intra-assay variability was 5%. All
Oslo samples were sent anonymously to Berlin for anti-
AT1RAb assessment, without information regarding the
patients’ clinical characteristics. The detection threshold of
anti-AT1R-Abs was set at 2.5 U/mL and maximum value
was given as 40.0 U/mL, which was the upper cut off limit.
Statistical analyses
Data were reported as median, range values with IQRs, or
as proportions and percentages (for the categorical
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variables). Comparisons between the groups were analyzed
using an unpaired t-test, Mann–Whitney U-test (for vari-
ables with skewed distribution). The strength of crude asso-
ciations between normally distributed continuous variables
was measured using Spearman’s correlation coefficient, as
the variables had a skewed distribution. Associations
between age, time since tx, donor source, rejections, and
GFR were analyzed by multivariate regression. All statistical
tests were two-sided, and a p-value <0.05 was considered sta-
tistically significant. All statistical analyzes were performed
using SPSS Statistics 18 (IBM company, Hong Kong).
Results
Table 1 presents a summary of clinical data from
the two transplanted cohorts as well as from the
two control cohorts. The cross-sectional study of
the 30 children (ped-tx) had a median age of
14 yr at HENT study inclusion (range 3–19 yr),
with a median time since tx of five yr (range 2–
14 yr) (Table 1). All were transplanted between
1993 and 2006. Mean age of the control group of
healthy of children (n = 51) was seven yr (range
5–8 yr) (Table 1). Regarding the control sub-
jects, there were no significant differences in time
since delivery for blood sampling between the
group of children with a mother from a hyper-
tensive pregnancy or from a non-hypertensive
pregnancy, nor differences in offspring gender,
BMI, systolic or diastolic blood pressure, or
MAP (13).
The group of 28 adults who were transplanted
at the age >16 yr (adult-tx) participated in the
HENT follow-up study at a median age of 26
(range 20–40 yr), with a median time since tx of
18 yr. All subjects in the adult-tx group were
transplanted between 1983 and 2002 (Table 1).
The adult control group consisted of 66 men
(33.3%) and 132 female (66.7%) subjects and
had a median age of 56.5 yr (range 42–83 yr).
The pediatric-tx group had a significantly
higher median total AT1RAb IgG concentration,
40.0 U/mL (IQR 14.48–40.0), compared with the
pediatric control group median 13.3 U/mL (IQR
7.49–38), p = 0.0006. Median total AT1RAb IgG
concentration was significantly higher in the ped-
tx group 40.0 U/mL (IQR 14.48–40.0) as com-
pared to the adult-tx group 10.95 U/mL (IQR
8.2–25.53), p < 0.0001. In contrast, the adult
transplanted group had a significantly higher
median total AT1RAb IgG levels 10.95, (IQR
8.2–25.53) U/mL than the adult control group
6.5 U/mL (IQR 2.5–9.3), p < 0.0001 (Fig. 1).
Sixteen of 30 patients in the pediatric-tx group
(53.3%) had levels >40.0 U/mL, in contrast to
21.6% in ped control, 17.8% in adult-tx group,
and none in the adult control group, respectively
(Fig. 1).
The healthy pediatric control group had simi-
lar median total IgG concentration as the adult-
tx group, 13.3 vs. 10.95 U/mL, p = 0.3 (Fig. 1).
There was no AT1RAb IgG level gender differ-
ence in the ped-tx group between girls (n = 11)
and boys (n = 19) (40.0 (9–40.0) U/mL vs. 40.0
(11–40.0) U/mL). Similar to the ped-tx group,
there was no gender difference for the adult
transplanted group (women 9 (2.5–40.0) U/mL
(n = 9) and men 11.9 (2.5–40.0) U/mL (n = 19)).
There was no difference in AT1RAb IgG levels
depending on the donor source, living-related
Table 1. Clinical characteristics of the participants
Ped-tx (n = 30) Adult-tx (n = 28) Ped controls (n = 51) Adult controls (n = 199)
Median age at blood sampling (range) 14 (3–19) yr 26 (20–40) yr 6.7 (4.8–8) yr 56.5 (48–83) yr
Male/female 19/11 17/11 20/31 140/59
Age at Rtx (yr) 7 (1–16) 13 (1–16) – –
Median time since Rtx years (range) 5 (2–14) 18 (7–27) – –
LD/DD (n, %) 1 Rtx 26/4; 87/13 23/5; 82/18 – –
2 Rtx 1/1 8/6 –
3 Rtx 1/1 0/3
Hypertension (n, %) 16/30, 53 23/28, 82 None None
Acute rejection (n, %) 5/30, 17 14/28, 50 – –
Median GFR (mL/min/1.73 m2) 50 (22–95) 56 (20–120)* – –
Etiology of ESRD (n) – –
CAKUT 11 7 – –
Glomerulonephritis 2 7 – –
Nephronophthisis 3 6 – –
HUS 1 1 – –
FSGS/CNF 4 2 – –
Metabolic† 4 – – –
Other diagnosis/unknown 5 5 – –
CNF, congenital nephrotic syndrome Finnish type.
*n = 27.
†Metabolic = cystinosis and primary hyperoxaluria type 1.
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donor (LD, n = 47) vs. DD (n = 11), median
18.7 U/mL, ([IQR 11.2–40.0] U/mL) vs. median
12.7 U/mL, ([IQR 6.7–40.0] U/mL), p = 0.183.
Donor source was considered as DD when more
than one transplantation was performed with
either LD or DD.
When analyzing the association of age with
elevated levels of AT1RAb IgG, there was a neg-
ative correlation between elevated levels and age
(r = 0.46, p = 0.0003). At the same time, the
longer the time since transplantation, the lower
the levels (r = 0.29, p = 0.04) (Fig. 2a,b).
In a multivariate linear regression of the trans-
planted groups adjusting for age at the HENT
study, LD vs. DDs, previous rejections, gender,
GFR, and time from tx to the HENT study, age
at tx was the only significant predictor for ele-
vated AT1RAb IgG levels at the HENT study
inclusion time (b = 1.063, p = 0.006).
Fifty-three percent in the ped-tx group and
82% in the adult-tx group were hypertensive at
the HENT study inclusion time, as defined
above. We found a tendency toward higher
AT1RAb IgG levels and hypertension (p = 0.13).
Data on exposure to previous rejections before
inclusion in the HENT study showed that there
was a difference in rejection rates between the
groups. The adult-tx group had by far more
rejections than the pediatric cohort, 50% as com-
pared to 17%. A previous rejection was poorly
associated with AT1RAb IgG levels (p = 0.11) in
the adult-tx group. Rejection events in the pedi-
atric group were rare so that statistical analysis
was not performed.
The AT1RAb IgG levels in the transplant
cohorts were spread evenly between the various
subgroups of transplant indication, with no cor-
relation with any diagnostic group (data not
shown).
Discussion
To our knowledge, this is the first report of
AT1RAb in a cohort of stable kidney recipients
transplanted in childhood. In this retrospective
study, our main findings were that the AT1RAb
levels were significantly higher both in children
and in adults transplanted in childhood
compared with healthy controls. Moreover, tx
Fig. 1. Individual AT1RAb IgG levels for the four study
groups: pediatric transplanted group (ped-tx), n = 30; pedi-
atric control group (ped-controls) n = 51; adult trans-
planted group (adult-tx), n = 28; and adult control group
(adult-controls), n = 199. Bars indicate median levels.
Highest cutoff level is 40 U/mL.






























p=0.0003, r=-0.46 p=0.04, r=-0.29
a b
Fig. 2. (a) Individual AT1RAb IgG levels in relation to age. Blue spots indicate the pediatric-tx group; red spots indicate the
adult-tx group. (b) Individual AT1RAb IgG levels in relation to time since tx. Blue spots indicate the pediatric-tx group; red
spots indicate the adult-tx group.
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children had significantly higher AT1RAb levels
compared to the adult-tx group. Age at tx was
the only significant predictor for elevated
AT1Rab levels.
HLA antibodies (HLA Ab) have well-recog-
nized associations with graft failure in kidney
transplantation (14). However, not all cases of
graft loss can be explained by the presence of
HLA Ab even when there are histological find-
ings consistent with AMR, and subsequently,
other antibodies have emerged as plausible cau-
sative agents. Several reports of elevated
AT1RAb have recently been published in connec-
tion with kidney transplant rejection (3, 4). How-
ever, the role of these autoantibodies in rejection
and graft loss following tx is not clear and under
investigation (1). The mechanism of autoanti-
body development is probably multifactorial and
not well understood. One hypothesis is that
patients develop autoantibodies to AT1 polymor-
phisms via the usual routes of allosensitization,
both as a consequence of blood transfusion and
as a transplantation (15) To what extent they are
responsible for injury to the microcirculation and
further amplification of cell damage still has to
be clarified (16).
The pathophysiological role of AT1RAb is
unknown, but in a rat model, purified AT1RAb
from patients with vascular rejection induced
renal artery muscular contractions after renal
ischemia and allogeneic transplantation. Pre-
treatment with a pharmacological ATR1 blocker
only partially inhibited the AT1RAb-mediated
contraction, which was almost completely abol-
ished by neutralizing peptides targeting epitopes
on the ATR1 receptor (17). In addition, it is
known that the autoantibodies stimulate the
receptor in an agonistic way and contribute to
vascular and perivascular inflammation (18).
According to in vitro studies, the AT1Rab may
contribute to inflammation, endothelial dysfunc-
tion, and atherosclerosis (7).
The human gene for AT1R is located on chro-
mosome 3 and so far several polymorphisms
have been identified, either mediating “loss of
function” or “gain of function.” Among these,
the A1166C polymorphism is associated with
increased responsiveness to AngII and various
cardiovascular and renal pathologies (2). In the
previously described pediatric case, the child was
homozygote for the AGTR1 gene A11166C poly-
morphism (8).
Among other interesting observations, renal
podocytes have been shown to express the AT1
receptor, and AngII regulates and enhances the
expression of TRPCP6, which leads to FSGS in
animal models (19). In the previously published
case of a child with AMR, the child had new-
onset collapsing FSGS. There has been another
published case in an adult with AMR, elevated
levels of AT1RAb and biopsy findings of focal
collapsing glomerulopathy. The detected ele-
vated levels of AT1RAb were successfully
removed by plasmapheresis and the condition
improved (20, 21).
Autoantibodies to AT1R have been associated
with other diseases, such as preeclampsia, sys-
temic sclerosis, and malignant hypertension (22,
23). A common feature of these diseases is the
dysfunction of diseased vessels with marked
inflammation and high thrombotic potential.
Women with a history of preeclampsia, and their
offspring, have an increased risk of CVD later in
life, and increased levels of biomarkers for CVD
have been shown to persist up to eight yr after
birth (13, 24). The relation between this long-
term health risk and presence of autoantibodies
to AT1R in pregnancy is not known. Current
hypotheses include the proposal that the pres-
ence of AT1Rab in pregnancy may mediate
increased sensitivity to AngII and the develop-
ment of pregnancy-related hypertension despite
unaltered levels of AngII in preeclampsia (22).
The presence of AT1RAb has also been found to
be associated with intrauterine growth restriction
(25). The presence of AT1RAb in pregnancy has
been shown by us to be present both in the
mother and in the fetus in preeclampsia (22).
Whether these autoantibodies also induce or
accelerate vascular dysfunction and could con-
tribute to atherosclerotic processes and increased
future cardiovascular risk, either for the mother
and/or for the offspring, is not known.
There are some limitations to our study. First,
this is a retrospective cross-sectional study, with
blood sampling at different time points after
transplantation. Second, data were not collected
at the time of rejection and information about
rejection was sampled from the NRR and from
searches in medical reports and journals. As
some data regarding rejections were historical,
not all rejections episodes could be clinically
categorized in details. None the less, even if the
rejection rate in the adult group was significantly
higher than in the pediatric group (50% vs. 17%,
resp), the AT1RAb levels in adults were signifi-
cantly lower than in the ped-tx cohort at HENT
inclusion. The longer interval from rejection may
be a plausible explanation for the adults having
lower IgG levels than the children with rejections
previously, but even so, the levels in the pediatric
control group were similar to the adult-tx group,
suggesting that the time from tx was not the only
relevant factor. Third, our samples sizes were
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small and the groups were heterogeneous with
respect to causes of end-stage disease and medi-
cal history. In addition, our control and patient
groups were not perfectly age matched.
Conclusion
AT1RAb total IgG levels were significantly
higher in a stable pediatric-tx cohort compared
to adult-tx patients and healthy controls of com-
parable age. The role of AT1RAb after renal
transplantation is still not defined. The relevance
of our findings in relation to age and time since
tx and the relation to rejection and CVD merits
future longitudinal studies.
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